HORSHAM, Pa.--(BUSINESS WIRE)--Neose Technologies, Inc. (NasdaqGM:NTEC) today announced that it received a milestone payment from Novo Nordisk A/S (NYSE:NVO) under a license agreement for the use of Neose’s GlycoPEGylation™ technology to develop a next-generation version of Factor IX. The Company is also working with Novo Nordisk under separate license agreements to develop GlycoPEGylated versions of recombinant Factors VIIa and VIII. A Phase I trial of GlycoPEG-Factor VIIa is currently ongoing.
